5,571 Shares in Dianthus Therapeutics, Inc. $DNTH Purchased by Persistent Asset Partners Ltd

Persistent Asset Partners Ltd acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,571 shares of the company’s stock, valued at approximately $543,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DNTH. Vestal Point Capital LP boosted its stake in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after buying an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Dianthus Therapeutics by 3,366.9% during the third quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock worth $101,431,000 after acquiring an additional 2,503,311 shares during the period. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after acquiring an additional 406,254 shares during the period. TCG Crossover Management LLC boosted its position in Dianthus Therapeutics by 11.7% in the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after purchasing an additional 175,000 shares during the last quarter. Finally, State Street Corp boosted its position in Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Insider Activity

In other news, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the completion of the transaction, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the transaction, the chief executive officer owned 65,292 shares of the company’s stock, valued at $7,058,718.12. The trade was a 71.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 284,306 shares of company stock valued at $29,289,369. 3.02% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DNTH. Truist Financial raised their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wedbush lifted their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $115.96 on Monday. The stock has a market capitalization of $6.34 billion, a PE ratio of -27.94 and a beta of 1.22. Dianthus Therapeutics, Inc. has a one year low of $19.84 and a one year high of $116.47. The business’s fifty day moving average price is $97.47 and its 200-day moving average price is $83.07.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. As a group, equities analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.